Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Vaxcyte, Inc. (PCVX : NSDQ)
 
 • Company Description   
Vaxcyte Inc.is a biopharmaceutical company develops vaccines for infectious diseases. It offers conjugate, pneumococcal conjugate and complex antigen-based vaccines. Vaxcyte Inc.is based in Foster City, California.

Number of Employees: 89

 
 • Price / Volume Information   
Yesterday's Closing Price: $25.32 Daily Weekly Monthly
20 Day Moving Average: 308,040 shares
Shares Outstanding: 58.31 (millions)
Market Capitalization: $1,476.51 (millions)
Beta: 0.41
52 Week High: $27.44
52 Week Low: $16.78
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 9.14% 22.93%
12 Week 12.03% 23.18%
Year To Date 6.43% 30.04%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
825 INDUSTRIAL ROAD SUITE 300
-
SAN CARLOS,CA 94070
USA
ph: 650-837-0111
fax: -
None http://www.vaxcyte.com
 
 • General Corporate Information   
Officers
Grant E. Pickering - Chief Executive Officer and Director
Andrew Guggenhime - President and Chief Financial Officer
Carlos Paya - Director
Annie Drapeau - Director
Kurt von Emster - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 92243G108
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/10/22
Share - Related Items
Shares Outstanding: 58.31
Most Recent Split Date: (:1)
Beta: 0.41
Market Capitalization: $1,476.51 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.69 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.70 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 4.73% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/10/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 4.09
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -65.85%
vs. Previous Quarter: -25.93%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -37.23
12/31/21 - -32.45
09/30/21 - -28.48
ROA
03/31/22 - -32.76
12/31/21 - -28.23
09/30/21 - -24.81
Current Ratio
03/31/22 - 12.56
12/31/21 - 8.93
09/30/21 - 6.38
Quick Ratio
03/31/22 - 12.56
12/31/21 - 8.93
09/30/21 - 6.38
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 6.17
12/31/21 - 5.38
09/30/21 - 5.86
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©